scholarly journals Correlation of COVID-19 with Parkinson’s disease and life expectancy indicates female population predominance in future

2021 ◽  
Vol 10 (Sp-Issue1 (COVID-19): S4-S12) ◽  
Author(s):  
Abdulrahman M. Alshahrani ◽  
Yusuf Jamal ◽  
Feras M. Almarshad ◽  
Aslam Pathan ◽  
Jamal M. Arif
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Life Expectancy ◽  
Female Population

MORTALITY IN PARKINSON'S DISEASE AND ATYPICAL PARKINSONIAN DISORDERS

2015 ◽  
Vol 86 (11) ◽  
pp. e4.88-e4
Author(s):  
Angus Macleod ◽  
Carl Counsell
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Life Expectancy ◽  
Median Survival ◽  
Lewy Body Dementia ◽  
Mortality Data ◽  
Kaplan Meier ◽  
Central Register ◽  
Population Mortality ◽  
Incident Cohort

BackgroundWe evaluated the mortality associated with Parkinson's disease (PD), Lewy body dementia (LBD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and vascular parkinsonism (VP) using a community-based incident cohort.MethodsAll incident parkinsonism cases identified over 4.5 years (2002-4, 2006-9) were tagged to the NHS central register for regular death notifications. Kaplan-Meier survival probabilities were plotted. Standardised mortality ratios (SMRs) and life expectancy, adjusted for age, sex and calendar year, were calculated using regional mortality data.ResultsUntil June 2014, 90 deaths occurred in 198 PD patients, and 107 deaths in 117 patients with other syndromes. Median survival in PD, LBD, PSP, MSA, and VP was 7.8 (6.7–9.4), 3.3 (2.3–4.1), 2.6 (1.1–3.8), 5.1 (1.3–NA), 2.1 (1.5–3.4) years, respectively. SMRs were 1.5 (1.2–1.9), 4.2 (3.0–5.9), 3.8 (2.6–5.5), 1.8 (0.9–3.4), 4.2 (3.0–6.0) respectively. In PD, median survival was lower than life expectancy, but more so in under 65s.ConclusionsMortality in PD was increased by 50% over expected population mortality. Younger patients have proportionally more to lose. Survival was much poorer in other syndromes.

Projections of prevalence, lifetime risk, and life expectancy of Parkinson's disease (2010-2030) in France

2018 ◽  
Vol 33 (9) ◽  
pp. 1449-1455 ◽  
Author(s):  
Mathilde Wanneveich ◽  
Frédéric Moisan ◽  
Hélène Jacqmin-Gadda ◽  
Alexis Elbaz ◽  
Pierre Joly
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Life Expectancy ◽  
Lifetime Risk

Marginal association between SNP rs2046571 of the HAS2 gene and Parkinson's disease in the Chinese female population

2013 ◽  
Vol 552 ◽  
pp. 58-61 ◽  
Author(s):  
Yi Yuan ◽  
Bei-sha Tang ◽  
Ri-li Yu ◽  
Kai Li ◽  
Zhan-yun Lv ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Female Population ◽  
Marginal Association

Increased life expectancy resulting from addition of l-deprenyl to Madopar� treatment in Parkinson's disease: A longterm study

1985 ◽  
Vol 64 (2) ◽  
pp. 113-127 ◽  
Author(s):  
W. Birkmayer ◽  
J. Knoll ◽  
P. Riederer ◽  
M. B. H. Youdim ◽  
Vera Hars ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Life Expectancy

Parkinson-kórban szenvedő betegek perioperatív ellátása. Irodalmi összefoglaló

2015 ◽  
Vol 156 (34) ◽  
pp. 1355-1359
Author(s):  
Béla Fülesdi ◽  
Calin Mitre ◽  
Csilla Molnár
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Life Expectancy ◽  
Statistical Data ◽  
Perioperative Complications ◽  
Management Strategies ◽  
Perioperative Period ◽  
Interdisciplinary Cooperation ◽  
Surgical Interventions ◽  
Proper Strategy

Similarly to an increase in life expectancy, the incidence of Parkinson’s disease increases as well. In parallel with this, more patients with Parkinson’s disease undergo elective or urgent surgical interventions. According to recent statistical data, more than half of the patients with Parkinson’s disease are not properly managed when they are hospitalized for surgical interventions. It is also clear that properly managed Parkinson’s disease patients have an approximately 50% lower rate for perioperative complications. The authors aimed to summarize the most important complications, the updated peri- and intraoperative treatment and management strategies of patients with Parkinson’s disease. They intended to underline that interdisciplinary cooperation and knowledge of the proper strategy may result in more successful treatment of Parkinson’s disease patients during the perioperative period. Orv. Hetil., 2015, 156(34), 1355–1359.

scholarly journals Oxidative Stress in Parkinson’s Disease: Potential Benefits of Antioxidant Supplementation

2020 ◽  
Vol 2020 ◽  
pp. 1-23
Author(s):  
Sandro Percário ◽  
Aline da Silva Barbosa ◽  
Everton Luiz Pompeu Varela ◽  
Antônio Rafael Quadros Gomes ◽  
Michelli Erica Souza Ferreira ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Parkinson’S Disease ◽  
Developing Countries ◽  
Parkinson's Disease ◽  
Life Expectancy ◽  
Antioxidant Supplementation ◽  
Potential Benefits ◽  
Underlying Mechanisms ◽  
Antioxidant Supplements ◽  
Number Of Individuals

Parkinson’s disease (PD) occurs in approximately 1% of the population over 65 years of age and has become increasingly more common with advances in age. The number of individuals older than 60 years has been increasing in modern societies, as well as life expectancy in developing countries; therefore, PD may pose an impact on the economic, social, and health structures of these countries. Oxidative stress is highlighted as an important factor in the genesis of PD, involving several enzymes and signaling molecules in the underlying mechanisms of the disease. This review presents updated data on the involvement of oxidative stress in the disease, as well as the use of antioxidant supplements in its therapy.

Phytochemicals and silk proteins in mature silkworm powders responsible for extended life expectancy and enhanced resistances to Parkinson's disease

2017 ◽  
Vol 20 (4) ◽  
pp. 1425-1433 ◽  
Author(s):  
Bo-Hye Choi ◽  
Sang-Deok Ji ◽  
Jong Gon Son ◽  
Phuong Nguyen ◽  
Kee-Young Kim ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Life Expectancy ◽  
Silk Proteins ◽  
Extended Life

scholarly journals Loss of p21-activated kinase Mbt/PAK4 causes Parkinson-like phenotypes in Drosophila

2021 ◽  
Author(s):  
Stephanie M Pütz ◽  
Jette Kram ◽  
Elisa Rauh ◽  
Sophie Kaiser ◽  
Romy Toews ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Life Expectancy ◽  
Emotional Behavior ◽  
Stressful Situation ◽  
Causative Role ◽  
Motor Impairments ◽  
Age Dependent ◽  
Negative Effect ◽  
P21 Activated Kinase

Parkinson's disease (PD) provokes bradykinesia, resting tremor, rigidity and postural instability but also non-motor symptoms such as depression, anxiety, sleep and cognitive impairments. Similar phenotypes can be induced in Drosophila melanogaster through modification of PD-relevant genes or the administration of PD-inducing toxins. Recent studies correlated deregulation of human p21-activated kinase PAK4 with PD, leaving open the question of a causative relationship of mutations in this gene for manifestation of PD symptoms. To figure out whether flies lacking the PAK4 homolog Mushroom bodies tiny (Mbt) show PD-like phenotypes, we tested for a variety of PD criteria. Here we demonstrate that mbt mutant flies show PD-like phenotypes including age-dependent movement deficits, reduced life expectancy and fragmented sleep. They also react to a stressful situation with higher immobility, indicating an influence of Mbt on emotional behavior. Loss of Mbt function has a negative effect on the number of dopaminergic protocerebral anterior medial (PAM) neurons, most likely caused by a proliferation defect of neural progenitors. The age-dependent movement deficits are not accompanied by a corresponding further loss of PAM neurons. Previous studies highlighted the importance of a small PAM subgroup for age-dependent PD motor impairments. We show that impaired motor skills are caused by lack of Mbt in this PAM subgroup. In addition, a broader re-expression of Mbt in PAM neurons improves life expectancy. Conversely, selective Mbt knockout in the same cells shortens life span. We conclude that mutations in Mbt/PAK4 can play a causative role in the development of Parkinson's disease phenotypes.

Sign in / Sign up

Export Citation Format

Share Document